MedTrace Logo

Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)

NCT01745640 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2026-02-05

No results posted yet for this study

Summary

The purpose of this study is to determine the efficacy and toxicity profile of Pomalidomide and Dexamethasone in relapsed or refractory Multiple Myeloma patients with deletion 17p or translocation (4;14)

Conditions

Interventions

DRUG

Dexamethasone

40mg (if patient \<75 years)/20mg weekly, oral route, on day 1, 8, 15, 22 per 28 days cycle

DRUG

POMALIDOMIDE

hard capsule 4mg/day, oral route, from day 1 to 21 per 28 days cycle

Sponsors & Collaborators

  • Celgene

    collaborator INDUSTRY

  • University Hospital, Lille

    lead OTHER

Principal Investigators

  • Xavier LELEU, PHD · CHRU de Lille

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2015-12-31
Completion
2015-12-31
FDA Drug
Yes

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01745640 on ClinicalTrials.gov